Celltrion Inc (068270) - Net Assets
Based on the latest financial reports, Celltrion Inc (068270) has net assets worth ₩17.35 Trillion KRW (≈ $11.76 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩22.33 Trillion ≈ $15.14 Billion USD) and total liabilities (₩4.98 Trillion ≈ $3.38 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore 068270 cash flow conversion to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩17.35 Trillion |
| % of Total Assets | 77.69% |
| Annual Growth Rate | 43.34% |
| 5-Year Change | 328.42% |
| 10-Year Change | 689.12% |
| Growth Volatility | 173.34 |
Celltrion Inc - Net Assets Trend (2007–2025)
This chart illustrates how Celltrion Inc's net assets have evolved over time, based on quarterly financial data. Explore Celltrion Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Annual Net Assets for Celltrion Inc (2007–2025)
The table below shows the annual net assets of Celltrion Inc from 2007 to 2025. For live valuation and market cap data, see 068270 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩17.35 Trillion ≈ $11.76 Billion |
-1.29% |
| 2024-12-31 | ₩17.58 Trillion ≈ $11.91 Billion |
+2.65% |
| 2023-12-31 | ₩17.13 Trillion ≈ $11.61 Billion |
+300.68% |
| 2022-12-31 | ₩4.27 Trillion ≈ $2.90 Billion |
+5.53% |
| 2021-12-31 | ₩4.05 Trillion ≈ $2.74 Billion |
+18.17% |
| 2020-12-31 | ₩3.43 Trillion ≈ $2.32 Billion |
+19.31% |
| 2019-12-31 | ₩2.87 Trillion ≈ $1.95 Billion |
+10.70% |
| 2018-12-31 | ₩2.60 Trillion ≈ $1.76 Billion |
+7.66% |
| 2017-12-31 | ₩2.41 Trillion ≈ $1.63 Billion |
+9.62% |
| 2016-12-31 | ₩2.20 Trillion ≈ $1.49 Billion |
+21.50% |
| 2015-12-31 | ₩1.81 Trillion ≈ $1.23 Billion |
+34.28% |
| 2014-12-31 | ₩1.35 Trillion ≈ $913.37 Million |
+23.98% |
| 2013-12-31 | ₩1.09 Trillion ≈ $736.73 Million |
+3.52% |
| 2012-12-31 | ₩1.05 Trillion ≈ $711.67 Million |
+16.74% |
| 2011-12-31 | ₩899.55 Billion ≈ $609.61 Million |
+15.34% |
| 2010-12-31 | ₩779.89 Billion ≈ $528.52 Million |
+173.00% |
| 2009-12-31 | ₩285.67 Billion ≈ $193.60 Million |
+30.02% |
| 2008-12-31 | ₩219.72 Billion ≈ $148.90 Million |
+726.32% |
| 2007-12-31 | ₩26.59 Billion ≈ $18.02 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Celltrion Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 32609.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩4.41 Trillion | 25.61% |
| Other Components | ₩12.80 Trillion | 74.39% |
| Total Equity | ₩17.21 Trillion | 100.00% |
Celltrion Inc Competitors by Market Cap
The table below lists competitors of Celltrion Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hannover Rück SE
F:HNR1
|
$28.80 Billion |
|
ResMed Inc
NYSE:RMD
|
$28.83 Billion |
|
GE HealthCare Technologies Inc.
NASDAQ:GEHC
|
$28.87 Billion |
|
Fortis Inc
TO:FTS
|
$28.93 Billion |
|
Dover Corporation
NYSE:DOV
|
$28.73 Billion |
|
Raymond James Financial Inc.
NYSE:RJF
|
$28.66 Billion |
|
China State Construction Engineering Corp Ltd
SHG:601668
|
$28.60 Billion |
|
Svenska Handelsbanken AB (publ)
ST:SHB-A
|
$28.54 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Celltrion Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 17,439,141,579,250 to 17,208,474,471,870, a change of -230,667,107,380 (-1.3%).
- Net income of 1,029,613,370,420 contributed positively to equity growth.
- Dividend payments of 153,763,509,730 reduced retained earnings.
- Share repurchases of 908,401,405,350 reduced equity.
- New share issuances of 11,930,046,000 increased equity.
- Other factors decreased equity by 210,045,608,720.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩1.03 Trillion | +5.98% |
| Dividends Paid | ₩153.76 Billion | -0.89% |
| Share Repurchases | ₩908.40 Billion | -5.28% |
| Share Issuances | ₩11.93 Billion | +0.07% |
| Other Changes | ₩-210.05 Billion | -1.22% |
| Total Change | ₩- | -1.32% |
Book Value vs Market Value Analysis
This analysis compares Celltrion Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.47x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 53.75x to 2.47x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | ₩3618.76 | ₩194500.00 | x |
| 2008-12-31 | ₩1833.60 | ₩194500.00 | x |
| 2009-12-31 | ₩2320.23 | ₩194500.00 | x |
| 2010-12-31 | ₩5872.06 | ₩194500.00 | x |
| 2011-12-31 | ₩6464.62 | ₩194500.00 | x |
| 2012-12-31 | ₩15241.17 | ₩194500.00 | x |
| 2013-12-31 | ₩7976.31 | ₩194500.00 | x |
| 2014-12-31 | ₩9153.69 | ₩194500.00 | x |
| 2015-12-31 | ₩12063.28 | ₩194500.00 | x |
| 2016-12-31 | ₩14176.19 | ₩194500.00 | x |
| 2017-12-31 | ₩15755.07 | ₩194500.00 | x |
| 2018-12-31 | ₩17054.25 | ₩194500.00 | x |
| 2019-12-31 | ₩19015.39 | ₩194500.00 | x |
| 2020-12-31 | ₩22740.16 | ₩194500.00 | x |
| 2021-12-31 | ₩26916.89 | ₩194500.00 | x |
| 2022-12-31 | ₩29926.22 | ₩194500.00 | x |
| 2023-12-31 | ₩81904.76 | ₩194500.00 | x |
| 2024-12-31 | ₩81039.61 | ₩194500.00 | x |
| 2025-12-31 | ₩78658.20 | ₩194500.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Celltrion Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.98%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 24.74%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.30x
- Recent ROE (5.98%) is below the historical average (11.23%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 9.04% | 3.81% | 0.98x | 2.43x | ₩-243.54 Million |
| 2008 | 6.63% | 17.41% | 0.17x | 2.27x | ₩-7.40 Billion |
| 2009 | 20.49% | 40.22% | 0.26x | 1.96x | ₩29.98 Billion |
| 2010 | 13.90% | 59.89% | 0.16x | 1.48x | ₩30.38 Billion |
| 2011 | 18.65% | 60.14% | 0.20x | 1.56x | ₩77.85 Billion |
| 2012 | 16.61% | 49.81% | 0.20x | 1.65x | ₩69.42 Billion |
| 2013 | 9.42% | 45.29% | 0.11x | 1.82x | ₩-6.26 Billion |
| 2014 | 9.03% | 23.92% | 0.20x | 1.86x | ₩-12.06 Billion |
| 2015 | 9.09% | 25.54% | 0.22x | 1.62x | ₩-15.33 Billion |
| 2016 | 8.67% | 26.54% | 0.22x | 1.47x | ₩-27.37 Billion |
| 2017 | 16.10% | 38.80% | 0.29x | 1.44x | ₩139.48 Billion |
| 2018 | 9.88% | 25.02% | 0.28x | 1.41x | ₩-2.90 Billion |
| 2019 | 10.91% | 26.68% | 0.29x | 1.40x | ₩25.02 Billion |
| 2020 | 15.65% | 28.00% | 0.37x | 1.52x | ₩186.99 Billion |
| 2021 | 14.79% | 30.31% | 0.34x | 1.45x | ₩187.74 Billion |
| 2022 | 12.99% | 23.55% | 0.39x | 1.42x | ₩123.90 Billion |
| 2023 | 3.15% | 24.61% | 0.11x | 1.17x | ₩-1.16 Trillion |
| 2024 | 2.42% | 11.88% | 0.17x | 1.21x | ₩-1.32 Trillion |
| 2025 | 5.98% | 24.74% | 0.19x | 1.30x | ₩-691.23 Billion |
Industry Comparison
This section compares Celltrion Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $226,935,679,293
- Average return on equity (ROE) among peers: 0.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Celltrion Inc (068270) | ₩17.35 Trillion | 9.04% | 0.29x | $28.76 Billion |
| ORIENTBIO Inc. (002630) | $44.21 Billion | 0.00% | 0.54x | $38.81 Million |
| Green Cross (005250) | $839.83 Billion | 8.01% | 3.90x | $443.37 Million |
| Green Cross Holdings Preference Shares (005257) | $1.10 Trillion | 3.96% | 0.48x | $3.97 Million |
| Pharmicell (005690) | $47.49 Billion | -26.70% | 0.24x | $652.66 Million |
| GeneOne Life Science Inc (011000) | $39.44 Billion | 3.58% | 0.21x | $72.32 Million |
| HLB Co. Ltd (028300) | $21.19 Billion | 0.00% | 1.56x | $4.53 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $21.14 Billion | 9.66% | 0.31x | $17.31 Million |
| Seoulin Bioscience Co.Ltd (038070) | $53.72 Billion | 4.89% | 0.32x | $38.04 Million |
| Hyundai Bioscience Co. Ltd (048410) | $18.90 Billion | 0.00% | 0.70x | $923.54 Million |
| iNtRON Biotechnology Inc (048530) | $83.77 Billion | -3.09% | 0.03x | $64.70 Million |
About Celltrion Inc
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for … Read more